Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomoramide SCHEMBL907811 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL548434 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL7474188 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL548433 | 0.94 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL9917087 | 0.93 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL9917086 | 0.88 | KDM4E (0.46) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL22313199 | 0.88 | L3MBTL1 (0.52) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL8741247 | 0.86 | ADRA2B (0.44) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL17028079 | 0.86 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL22313196 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10741 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4714444-A1 | PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS | Changchun Institute Of Applied Chemistry Chinese Academy Of Sciences (CN) | 2026-03-25 | — | — | EP | claimed |
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-0415693-A1 | Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence | ARIZONA TECHNOLOGY DEVELOPMENT CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| EP-0377518-A2 | Sustained release pharmaceutical composition | F.H. FAULDING & CO. LIMITED (AU) | 1990-07-11 | — | — | EP | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4879298-A | ADMINISTERING FORSKOLINE TO POTENTIATE ANALGESIC EFFECTS OF NARCOTICS | ROUSSEL UCLAF (FR) | 1989-11-07 | — | — | US | claimed |
| EP-0287469-A1 | Mixture containing as the active principles a central analgesic and forskolin | ROUSSEL-UCLAF (FR) | 1988-10-19 | — | — | EP | claimed |
| US-4760070-A | Administering central analgesic and sufficient adenine | ROUSSEL UCLAF (FR) | 1988-07-26 | — | — | US | claimed |
| EP-0108017-B1 | MIXTURE COMPRISING A CENTRAL ANALGESIC AND VITAMIN B12, OR ONE OF ITS ANALOGS, AS ACTIVE PRINCIPLES | ROUSSEL-UCLAF (FR) | 1986-12-10 | — | — | EP | claimed |
| US-4522816-A | VITAMIN B12 OR DERIVATIVE ADDED TO POTENTIALIZE CENTRAL ANALGESIC WITH REDUCED TOXICITY | ROUSSEL UCLAF (FR) | 1985-06-11 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
| US-4053604-A | 3-HYDROXY-3-ISOPROPYL-2,3,4,4A,8,9,13B,14-OCTAHYDRO-1H -BENZO(6,7)CYCLOPENTA(1,2,3-DE)PYRIDO(2,1-A)ISOQUINOLIN-3-OL | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1977-10-11 | — | — | US | claimed |